ARCA Biopharma Inc. (Nasdaq: ABIO), a Westminster company known for its focus on genetically targeted therapies for cardiovascular diseases, has announced a significant update regarding its corporate strategy and planned merger with Oruka Therapeutics Inc. As part of the merger, ARCA plans to divest its legacy technology and intellectual property, including assets related to Gencaro…
This Article Is Locked, But Not Out of Reach
Jeffco BdB delivers smart insights on local businesses. Get a free account to unlock rankings, trends, and alerts tailored to you.
Curious how it works? Watch the Quickstart
Want everything unlocked? See Paid Options
Already a member? Log in here